Kiniksa (KNSA) Pharmaceuticals announced that the U.S. Food and Drug Administration granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis, which includes recurrent pericarditis. KPL-387 is an independently developed monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting the signaling activity of the cytokines interleukin-1alpha and interleukin-1beta.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa price target raised to $50 from $45 at Citi
- Kiniksa granted orphan designation for treatment of pericarditis
- Kiniksa price target raised to $44 from $38 at Wedbush
- Kiniksa Pharmaceuticals: Strong Buy Rating Driven by Arcalyst’s Market Success and Promising Pipeline
- Kiniksa initiated with a Buy at TD Cowen